CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
Franken et al. examine the mechanisms that differentiate combined therapy with anti-CTLA4 and anti-PD-L1 from anti-PD-L1 monotherapy in head and neck squamous cell carcinoma (HNSCC). Single-cell analyses of the tumor microenvironment, tumor-draining ly…